Physician profile
Sandor Mecs
NPI 1568426419
$190,486.20
in general payments reported to CMS, 2019-2025
23 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $8,962 · 2021: $45K · 2022: $59K · 2023: $23K · 2024: $8,771 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $51K · Travel and Lodging: $4,086 · Food and Beverage: $3,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $50,600.00 |
| Travel and Lodging | $4,086.47 |
| Food and Beverage | $3,462.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $189,246.19 | 2019-2025 | Da Vinci Surgical System |
| Abbvie INC. | $226.81 | 2019-2022 | |
| Coopersurgical, INC. | $124.50 | 2025 | Ally II Ups |
| Cumberland Pharmaceuticals, INC. | $115.59 | 2019-2024 | Caldolor |
| Pfizer INC. | $106.15 | 2021-2025 | |
| Astellas Pharma US INC | $77.12 | 2019-2023 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $72.53 | 2022-2025 | |
| Organon LLC | $69.80 | 2021-2024 | |
| Medtronic, INC. | $66.15 | 2023 | Endurant Iis |
| Sumitomo Pharma America, INC. | $50.36 | 2023 | Myfembree |
| Exeltis, USA INC. | $34.75 | 2022-2024 | Slynd |
| Agile Therapeutics, INC. | $34.33 | 2021 | |
| Myovant Sciences INC. | $33.88 | 2022 | |
| Axonics, INC. | $32.91 | 2021 | |
| Amag Pharmaceuticals, INC. | $31.34 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $29.37 | 2021-2024 | Pico |
| Alydia Health | $27.37 | 2021 | |
| Evofem Biosciences, INC. | $27.34 | 2021 | |
| Merck Sharp & Dohme LLC | $18.90 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.68 | 2020 | |
| Ethicon US, LLC | $17.86 | 2022 | |
| Baxter Healthcare | $12.30 | 2022 | |
| Minerva Surgical, INC | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandor Mecs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.